BDx firmly believes that there is an urgent and profound need for such a technology to mitigate the effects of the LC epidemic.  This technology will greatly benefit LC patients, physicians and insurers.  Strategic investments will enable BDx to bring this technology to the marketplace and thus help millions of cancer patients in the US and worldwide.

BDx aims to be the preeminent leader in breath analysis worldwide.  To this effect BDx is seeking partners in the US, Europe and China to develop and commercialize the OneBreath technology.  The company currently is raising Seed Preferred funding ($2.2M) for design and development efforts and to complete independent clinical validation studies.